2026-W24

# Weekly Position Deep-Dive — W3
**ISO Week:** 2026-W24 (matches this cycle's W1/W2 markers; W4 reads all three together) | **Research as of:** Sun 2026-06-07 (after the trading week Mon 6/1 → Fri 6/5; next session Mon 6/8 cash open)
**Scope:** Strategy B open positions — **HCA, ZBRA, TJX, AZO**. Strategies A / C / E flat (zero open positions). Strategy D excluded per W3 spec (RTX and DIS covered in M3).
**Book change since last W3 (2026-W23):** BRC and BURL both closed during the prior week (both reached convergence). The B book is now four longs (down from six). `state.current_positions` confirms: HCA, ZBRA, TJX, AZO (B) + RTX, DIS (D, out of scope).
**Sources:** BigQuery `state.current_positions` (open book + convergence/time-exit/conviction), `state.current_regime` (router), `events.decision_log` (GO thesis entries: HCA 2026-04-27, ZBRA 2026-05-13, TJX 2026-05-23, AZO 2026-05-27); Strategy.md (B exit rules §"Exit rules and thesis invalidation"); Operating_Protocols.md (§8 conviction, §11 connector); B_Sub_Pattern_Taxonomy.md; last cycle's Weekly_Position_Deep_Dive.md (2026-W23) for original invalidation criteria. IBKR connector `get_price_history` (dated daily bars — authoritative closes). Tavily / web research 6/7 (per-position citations inline).

> **Data-integrity notes:**
> 1. **`get_price_snapshot` was one session stale across ALL FOUR names on this Sunday pull** — its `prior-close` / `last(is_close)` returned the **Thursday 6/4** close, not Friday 6/5. Authoritative 6/5 closes from `get_price_history` (dated bars): **HCA $372.13** (snapshot showed $361.83 = 6/4), **AZO $3,116.43** (snapshot $3,081.94 = 6/4), **TJX $160.71** (snapshot $158.63 = 6/4), **ZBRA $232.11** (snapshot $245.48 = 6/4). All marks/gaps below use the corrected 6/5 closes. **Standing recommendation for D1/D2:** when precision near a convergence target matters, prefer `get_price_history` dated bars over `get_price_snapshot` `prior-close`, which can lag a session on weekend/pre-market pulls.
> 2. **HCA** continued lower Mon–Thu (6/1 $370.96 → 6/4 $361.83 week-low) then bounced Fri to **$372.13 (+2.85%)** on a Bernstein "more attractive at these levels" note. Mark is **−14.1%** vs cost; convergence $442.85 = **+19.0%** above spot with only **~20 days** to the 6/27 time-exit. Time-expiry resolution is now the overwhelmingly likely path.
> 3. **ZBRA** fell **−5.4% on Fri 6/5** ($245.48 → $232.11) in the market-wide, yields-driven risk-off after the hot May jobs print — an adverse **mark without ZBRA-specific news** (NOT an exit trigger for a B long). Mark now −7.0% vs cost; convergence $264 = +13.7% above spot.
> 4. **AZO and TJX both recovered toward target** and now sit within ~2.4–2.7% of convergence (AZO +2.7% to $3,200; TJX +2.4% to $164.50). D1/D2 daily watch should stage the convergence SELL on the first **close ≥ target** per Strategy.md (META/IBM first-close-above precedent).

---

## IMMEDIATE-ACTION: NONE

No open position has a tripped invalidation criterion this week. All four are **HOLD**. The deepening adverse mark on HCA (−14.1%) and the −5.4% Friday drop on ZBRA are **adverse mark-to-market without thesis news** — Strategy.md gives B **longs** no price stop (the rev-13 stop-loss applies only to shorts; this book is all long), so neither is an exit trigger. HCA carries an **ELEVATED time-expiry watch** (likely closes on the 6/27 60-day stale exit), but that is a mechanical time-exit, not an invalidation, and the 6/27 time-exit is already the resolution path. No W4 exit-staging is owed this cycle.

---

## Strategies A, C, E — No Open Positions

- **Strategy A:** Zero open. Router **DO-NOT-ACTIVATE** (`state.current_regime` STRATEGY_ACTIVATION A, as-of 2026-06-03, unchanged from April). Nothing to deep-dive.
- **Strategy C:** Zero open structures. Router **HYBRID ACTIVATE** (div-C-202605-1, MIXED). Next FOMC 2026-06-16/17 is the gating event window. Nothing open to deep-dive.
- **Strategy E:** Zero open pair positions. Router **ACTIVATE but execution-feasibility-deferred** at current book size (ETF-substitution-required per M3 / div-E-202605-1). Nothing to deep-dive.

---

## Strategy B — Open Position Deep-Dives

**Router state:** B router **ACTIVATE** (`state.current_regime`: STRATEGY_ACTIVATION B = ACTIVATE; SPY_TREND = NEUTRAL ≠ DOWN; EQUITY_BREADTH = HEALTHY; VIX ≠ HIGH; SUSTAINED_INVERSION NOT-SUSTAINED). The Fri 6/5 single-day risk-off (hot May jobs print → yields spike → Nasdaq ~−4%) does **not** flip the technical clauses (Trend ≠ DOWN, VIX ≠ HIGH); formal re-call is owned by the monthly M1. FUNDAMENTAL_AXIS integrative read: **stagflation-tilt + risk-on** (decelerating growth, reaccelerating inflation, hawkish policy, risk-on sentiment, latent shock).

**B book — corrected closes (Fri 2026-06-05, `get_price_history`):**

| Position | Status | Fill date | Fill px | Cost basis (incl. comm) | Shares | Convergence target | 6/5 close | Δ vs cost | Δ to target | Time-based exit | Days to time-exit | Conviction |
|----------|--------|-----------|---------|--------------------------|--------|--------------------|-----------|-----------|-------------|-----------------|-------------------|------------|
| HCA  | OPEN | 2026-04-28 | $433.46 | $28.11 | 0.0642 | $442.85 | **$372.13** | **−14.1%** | +19.0% | 2026-06-27 | **~20** | MEDIUM-LOW |
| ZBRA | OPEN | 2026-05-14 | $249.52 | $37.90 | 0.1505 | $264.00 | **$232.11** | **−7.0%** | +13.7% | 2026-07-13 | ~36 | MEDIUM-HIGH |
| TJX  | OPEN | 2026-05-26 | $158.50 | $37.53 | 0.2346 | $164.50 | **$160.71** | +1.4% | +2.4% | 2026-07-24 | ~47 | MEDIUM-LOW |
| AZO  | OPEN | 2026-05-27 | $3,110.69 | $37.99 | 0.0121 | $3,200 | **$3,116.43** | +0.2% | +2.7% | 2026-07-24 | ~47 | MEDIUM-LOW |

**Cross-cuts:** Four concurrent B longs spanning Health Care Facilities (HCA), Communications Equipment / AIDC (ZBRA), Apparel Retail off-price (TJX), Automotive Retail (AZO). Per Strategy.md rev-35 (owner directive) there is **no per-GICS holdings-count cap**; concurrent-position correlation is monitored (KL #12 metric (d)), never capped. The apparel-pair concentration that dominated last cycle's correlation watch (TJX × BURL) is gone with BURL's exit; TJX is now the only off-price name.

---

### HCA Healthcare (OPEN — thesis intact but stalling; policy de-rating, not invalidation; ~19% below target with ~20 days left)

**1. Current thesis status.** Thesis (Q1-print overshoot reverts ~25% toward $442.85) still technically *holds* on its own terms — no invalidation criterion has tripped — but convergence has not materialized and narrative drift is now firmly *against* it. HCA fell every day Mon–Thu (IBKR closes: 6/1 $370.96, 6/2 $367.35, 6/3 $363.23, 6/4 $361.83 — the week's low), then bounced Friday to **$372.13 (+2.85%)** on a Bernstein "more attractive at these levels" note. Spot is ~−14.1% vs the $433.46 cost basis; the $442.85 target sits ~**+19.0%** above the 6/5 close (still implausibly far). The week's decline was *sector/policy de-rating* (Bernstein cut its EV/EBITDA multiple to 8x from ~9.3x), not an HCA-specific shock — i.e., already-priced slow-drip Medicaid/SDP overhang continuing to compress the multiple, exactly the "structural overhang" the original thesis flagged. The overshoot-reversion premise has been overwhelmed by ongoing multiple compression.

**2. Competitive landscape.** Sector-wide pressure, no idiosyncratic peer shortfall print. **Community Health (CYH)** completed the sale of four Arkansas hospitals to Freeman Health for **$110M** (6/1–6/2, Zacks/TipRanks/GuruFocus) — debt-reduction/de-risking, not a fundamentals event. **Tenet (THC)** ~$163 (Trefis 6/3), no new print this week (next earnings 7/28; Q1 was strong with ~16.7% adj-EBITDA margin and ~70% commercial/managed-care mix, structurally less Medicaid-exposed than HCA). No new UHS development in-week. Peers confirm a *macro/policy* hospital repricing, not an HCA-specific deterioration — consistent with criteria (iii)/(iv) remaining cleared.

**3. Fundamental developments.** No HCA filing, guidance change, or business update in 6/1–6/5. HCA-specific items are immaterial: the **College of Health Care Professions** acquisition (announced 5/27, labor-pipeline, regulatory-pending) and a **CareNow** 17-clinic Carolinas urgent-care add — both small bolt-ons, thesis-neutral. A **Cigna network agreement** reached 6/2 (WTOC/WALB) is the regional **Memorial Health/Savannah** contract resolution — modestly positive locally, not firm-wide material. Dividend $0.78, ex-date 6/16 — routine. **Analyst action (the week's key event): Bernstein SocGen (Lance Wilkes) cut PT to $413 from $503 on 6/4**, Market Perform maintained, citing policy risk, slower EBITDA growth (projecting +2.8% 2026 / +4.6% 2027), lower insurance coverage and "lack of growth in state directed payments," EV/EBITDA to 8x, and "no near-term catalyst." (JPMorgan's $490-from-$535 cut was 5/19, pre-window.) Even the cut $413 target sits ~11% above spot; Street consensus still ~$510+.

**4. Sector / macro context.** Dominant in-week macro item: **CMS published the interim final rule on Medicaid work/community-engagement requirements** (Federal Register 6/3; Alliance of Safety-Net Hospitals 6/4) — 80 hours/month for expansion-population adults, effective for applications on/after 1/1/2027, comment to 7/31/2026. This is **implementation detail of the already-enacted H.R.1 (signed 7/4/2025)**, not a new policy shock. HMA's 6/3 roundup notes CMS is advancing a broader state-directed-payment (SDP) recalibration, but **no new SDP rule landed this week** — it remains the known overhang (H.R.1's SDP step-downs begin Oct 2027). The week's price action reflects sentiment/multiple drift on **already-priced** policy, not fresh information — which by B-strategy rules is explicitly *not* an exit trigger for a long.

**5. Thesis-invalidation signals.**
- **(i) FY26 guide cut below floors ($76.5B rev / $15.55B adj EBITDA / $29.10 EPS): NOT-TRIPPED.** Guidance reaffirmed at Q1 (4/29), unchanged; no update in-window. Bernstein's external EBITDA-growth skepticism is sell-side modeling, not a company guide cut.
- **(ii) HCA pre-announcement / negative business update: NOT-TRIPPED.** Only in-week HCA news (Cigna-Savannah resolution, bolt-on M&A, dividend) is neutral-to-positive.
- **(iii) THC sector-wide shortfall print: NOT-TRIPPED** (resolved at staging; no new THC print this week).
- **(iv) UHS corroboration: CLEARED** (no adverse UHS development in-window).
No criterion tripped. The Bernstein downgrade is adverse *sentiment/macro* on already-priced policy — explicitly not an invalidation.

**6. Time to thesis resolution.** Effectively no realistic path to target. With **~20 days to the 6/27 time-exit** and the $442.85 target ~+19% above the 6/5 close, convergence would require a ~19% rally in three weeks with **no scheduled catalyst** before it — Q2 earnings are **7/24**, after the exit. Bernstein explicitly flags "no near-term catalyst." The Friday +2.85% bounce is an oversold-relief move off ~$360 support, not thesis vindication. Overwhelmingly likely resolution: the **6/27 60-day stale exit**, closing below both cost and target.

**Recommendation: HOLD (to the 6/27 time-based exit).** No invalidation criterion (i)–(iv) tripped — the week's weakness is adverse mark-to-market on already-priced Medicaid/SDP policy plus a sell-side PT cut, which B-strategy rules expressly exclude as a trigger for a long (no price stop). Convergence to $442.85 by 6/27 is implausible (~+19% needed, no catalyst before Q2 on 7/24), so the **6/27 60-day time-exit is the cited resolution rule** (Strategy.md "Timeline expiry at 60 days from entry"). No W4 exit-staging this cycle — the mechanical time-exit fires 6/27; D1's daily sweep should flag the time-exit hit for D2 staging on/after 6/27.

---

### Zebra Technologies (OPEN — thesis intact; no adverse ZBRA-specific news; Friday macro drop widens the gap)

**1. Current thesis status.** Thesis HOLDS — no new ZBRA-specific negative information in 6/1–6/5. The week's two ZBRA events were neutral-to-positive: (a) **ZONE 2026 customer conference** (6/1–6/4, Nashville), where Zebra launched a software-portfolio expansion — "Zebra Nucleus" unified device-management platform plus "Workcloud IO" and "Workcloud BI" AI solutions (Business Wire / Zebra newsroom 6/2); shares rose +1.79% on the 6/2 announcement. (b) **William Blair 46th Annual Growth Stock Conference** (6/4; CFO Nathan Winters + IR VP Mike Steele), where management reiterated broad-based demand and the post-Q1 framework with no walk-back. Per the corrected 6/5 close of **$232.11** the position is ~**−7.0% vs the $249.52 cost basis** and the $264 convergence target sits ~**+13.7% above spot**. The thesis narrative is undamaged, but the gap-fill math is meaningfully harder after Friday.

**2. Competitive landscape.** No adverse peer signals; if anything, structurally supportive. Honeywell continued exiting AIDC-adjacent hardware — its Warehouse & Workflow Solutions (Intelligrated/Transnorm) sale to American Industrial Partners and PSS sale to Brady both remain on track to close 2H26, and the Aerospace spin-off was set to 6/29/2026 — Honeywell is shrinking as a direct AIDC competitor, a modest tailwind. Datalogic was in normal product-launch cadence (Falcon X60/X65, Skorpio X40/X45 at MODEX 2026), not a share-shift event. No 6/1–6/5 negative read-through from Cognex, Motorola Solutions, Ciena, or Lumentum bearing on ZBRA's AIDC demand.

**3. Fundamental developments.** No SEC filings, no guidance changes, and — critically for criterion (iv) — **no new sell-side rating or PT actions during 6/1–6/5.** Every recent action is the post-Q1 (5/12 BMO) wave dated 5/13–5/14: KeyBanc upgrade to Overweight $305; Baird Outperform $300→$310; Barclays Overweight $330→$345; Citi Neutral $274→$284; Needham Buy $345; BNP Paribas Outperform $370; Truist Buy $267. Consensus PT ~$307–336; rating mix ~8 Buy / 5 Hold / 0 Sell (MarketBeat, Benzinga, StockAnalysis). The only conference appearance in-window (William Blair 6/4) produced a reaffirmation, not a re-rating. Zacks noted 5 upward FY26 EPS estimate revisions in the trailing 60 days (consensus $18.57), consistent with — and already inside — the thesis.

**4. Sector / macro context.** Dominant 6/1–6/5 development was macro, not company-specific. Friday 6/5 broad risk-off: "Dow falls 695 points after U.S. jobs report; S&P 500 and Nasdaq book biggest percentage drops since 2025… Treasury yields jump" (MarketWatch live blog 6/5) — a strong May payrolls print (~172K, ~2× consensus) spiked yields and hit tech/rate-sensitive names. ZBRA's ~−5.4% on 6/5 is consistent with high-beta tech drawdown, not a demand/fundamental shock (Quiver earlier framed a similar ZBRA dip as "post-earnings momentum cools amid broader tech pullback"). Section 232 semiconductor tariffs remain an open *sector* overhang (ITIF 6/4; White House July 1 review), but nothing ZBRA-specific surfaced; a 6/1 metals-tariff proclamation actually added a targeted reduction tier for certain industrial-equipment inputs.

**5. Thesis-invalidation signals.**
- **(i) FY26 framework reset (EPS < $18.30 mid / sales-guide retraction / adj-OM < 24.5%): NOT-TRIPPED.** No guide change; framework reaffirmed in tone at William Blair 6/4; estimate revisions upward (Zacks $18.57).
- **(ii) Demand / customer-weakness pre-announcement: NOT-TRIPPED.** Opposite signal — ZONE 2026 product launches + CFO's reiteration of broad-based demand. No pre-announcement.
- **(iii) Tariff-regime ZBRA-specific adverse disclosure: NOT-TRIPPED.** No ZBRA-specific tariff disclosure 6/1–6/5; management stance unchanged (no material FY26 tariff impact expected; Section 232 monitored, "nothing really to specifically comment on"). Macro Section-232 noise is not a ZBRA disclosure.
- **(iv) Sub-pattern-1 cluster escalation (≥3 aggressive +10% PT raises): NOT-TRIPPED.** Zero new PT actions in 6/1–6/5; the post-print cluster was 5/13–5/14 (mostly single-digit %, pre-window). No re-rating-to-equilibrium wave this week.

**6. Time to thesis resolution.** ~36 days to the 7/13 stale-exit; next hard catalyst (Q2 print) is ~8/4 — **after** the exit, so no fundamental catalyst remains in-window to force the gap-fill. Convergence now requires ~+13.7% from $232.11 in ~5 weeks with no scheduled company catalyst and a freshly hostile rate/macro tape — materially less probable than at entry. No invalidation tripped; the 6/5 move was macro beta (adverse mark without news), which B-strategy rules exclude as a trigger.

**Recommendation: HOLD.** No invalidation criterion (i)–(iv) tripped — the week produced reaffirmation (William Blair 6/4) and positive product news (ZONE 6/2); the only material price action (−5.4% on 6/5) was a market-wide, yields-driven tech selloff, i.e., an **adverse mark without thesis news**, which B-strategy rules exclude as an exit trigger (cited rule: Strategy.md "Adverse mark-to-market without news (long positions only) — Not exit-triggering"). Thesis intact; probability of reaching $264 by 7/13 has fallen, but conviction re-scoring on the corrected math is a sizing observation, not an invalidation exit. Watch criterion (iv) for any incipient ≥3-firm aggressive PT-raise wave.

---

### TJX Companies (OPEN — thesis intact, drifting toward target on relative strength; no invalidation, no completion)

**1. Current thesis status.** Thesis HOLDS with no negative drift. No TJX-specific fundamental news hit the 6/1–6/5 tape — the only company-specific items were routine/non-thesis: a $0.48 quarterly dividend paid 6/4 (record 5/14), and insider Form-4/Rule-144 activity (SEVP Kenneth Canestrari sold 31,447 sh @ ~$157.50 on 6/3; CEO Ernie Herrman dispositions 6/3–6/4 ~29.5K + 28K sh; EVP Peter Benjamin gifted 68,258 sh to a trust 6/4) — pre-arranged/estate-planning style, not a thesis signal (StockTitan SEC filings 6/3–6/4). A Yahoo Finance/Simply Wall St piece (6/1) characterized the story as "steady price target… no change" — i.e., the Street has NOT re-rated post-print, consistent with the "under-rated beat-and-raise" premise still being live. Per the corrected 6/5 close of **$160.71** the position is ~+1.4% above the $158.50 cost basis and only ~**+2.4%** below the $164.50 target. Price action corroborates: TJX rose to $160.71 on Fri 6/5 with notable **relative strength** even as the Nasdaq fell ~−4.2% / S&P ~−2.6% on the hot jobs print.

**2. Competitive landscape.** Off-price peer read-through is uniformly POSITIVE and reinforces the trade-down/share-gain thesis. Ross Stores (ROST) recently printed a blowout — total sales $6.0B (+21% YoY, ~$360M above consensus), comps +17%, raised FY comp guide to +6–7% and EPS to $7.50–7.74 (Yahoo Finance/TIKR). Burlington (BURL) printed beat-and-raise 5/28 (adj EPS $2.10 vs ~$1.80 cons; sales +14% to $2.85B; comps +6%; FY adj-EPS raised to $11.45–11.80). Both confirm the off-price category is taking share in a pressured-consumer tape — directly supportive. No Walmart/Target formal off-price channel launch surfaced; WMT/TGT in-week news was promotional-calendar only (Walmart Deals 6/22; Target Circle Days 6/23–26). Structural caveat already in the thesis: ROST/BURL/TJX are all expanding units aggressively — a longer-run competition-for-sites dynamic, not a 1-week event.

**3. Fundamental developments.** No analyst rating/PT changes dated within 6/1–6/5. Most recent notable sell-side action remains UBS raising its PT to $197 (from $193), Buy — but that was 5/21 (post-print), already priced and outside this week. Consensus context: average/median PTs ~$166–175 with a Strong Buy/Buy skew (~94% Buy-or-better) (MarketBeat/StockAnalysis). No conference appearances, 8-Ks, or estimate revisions specific to the week.

**4. Sector / macro context.** Mixed-to-cautious macro, net neutral-to-supportive for off-price. The May payrolls print (released 6/5) was hot at 172K (~2× consensus), unemployment 4.3%, spiking yields and triggering a "good news is bad news" risk-off (Nasdaq −4.2%, S&P −2.6%, Dow −695; TheStreet/CNBC 6/5). Apparel/discretionary read-through was bifurcated: Lululemon (LULU) cut FY guidance and fell ~13% premarket — a high-end/full-price casualty that, if anything, **reinforces** the G-shaped trade-down narrative favoring off-price. Tariff backdrop persists (apparel prices ~+8% YoY), pushing consumers toward value channels — structurally supportive. TJX's relative strength on a −4% Nasdaq day is the most telling tape signal of the week.

**5. Thesis-invalidation signals.**
- **(i) FY27 comp guide below 2–3% floor / pretax margin below 11.7% floor: NOT-TRIPPED.** No 8-K or guidance revision in-week; last guide was the 5/20 beat-and-raise (raised across all metrics). Peer prints (ROST, BURL) raised guides, lowering odds of a near-term TJX cut.
- **(ii) Structural off-price competitive change (WMT/TGT formal aggressive off-price launch): NOT-TRIPPED.** No such announcement; WMT/TGT in-week news was routine promotional calendars only.
- **(iii) Sub-pattern-1 escalation (≥3-firm ≥20% aggressive PT-raise wave to ~$185–190): NOT-TRIPPED.** No clustered PT-raise wave in 6/1–6/5; the lone $197 UBS PT is pre-window (5/21) and isolated. Information-priced equilibrium has not formed.
None tripped.

**6. Time to thesis resolution.** ~47 days to the 7/24 stale-exit. With spot ~$160.71 the gap to the $164.50 target is only ~**+2.4%** — convergence is closer than the stale mark implied and TJX is grinding toward it on relative strength. No catalysts before 7/24 (Q2 FY27 print is mid-to-late August, after exit), so resolution hinges on continued passive gap-fill rather than a discrete event; supportive peer tape and value-channel macro raise the odds of touching $164.50 within the window.

**Recommendation: HOLD — APPROACHING TARGET.** No invalidation criterion tripped (i/ii/iii all NOT-TRIPPED) and the convergence target ($164.50) is not yet reached — neither B exit gate is met, and 47 days remain. The week's evidence (TJX relative strength on a −4% market day; ROST/BURL beat-and-raises; LULU's high-end miss reinforcing trade-down) is net-confirmatory. **D1/D2 daily watch:** if TJX closes ≥ $164.50 on any session, stage the convergence SELL immediately per Strategy.md "Convergence target reached" (META/IBM first-close-above precedent). Watch criterion (iii) for any incipient ≥3-firm PT-raise cluster toward $185–190.

---

### AutoZone (OPEN — thesis intact; +6.2% recovery off the 52-wk low; PT-cut watch DE-ESCALATED; target now only ~+2.7% away)

**1. Current thesis status.** Thesis HOLDS. AZO recovered through the entire window: IBKR daily closes 6/1 $3,020.95 → 6/2 $3,029.36 → 6/3 $3,061.65 → 6/4 $3,081.94 → **6/5 $3,116.43**. The bounce off the 5/29 52-wk-low ($2,935.19) is ~**+6.2%**, and AZO now sits ~**+0.2% above the $3,110.69 cost basis** (not under it). The recovery has no single hard catalyst — it reads as the post-overreaction mean-reversion the Strategy-B thesis predicted, supported by constructive items (TD Cowen Buy reiteration 6/4; Vendor Summit / mega-hub expansion 6/3) and the **absence of any new bad news**. Narrative drift is mildly positive (coverage volume elevated ~28 vs ~11 avg per MarketBeat; tone shifted from the 5/26 "miss + 52-wk low" framing toward execution/strategy).

**2. Competitive landscape.** No new peer prints in-window (auto-parts retailers reported Apr–May). Context only: O'Reilly (ORLY) posted record Q1 revenue/EPS; Advance Auto Parts (AAP) Q1 revenue $1.97B (−1.2% YoY) but beat EPS and raised FY EPS guide; Genuine Parts (GPC) reaffirmed FY26 (3%–5.5% sales growth) at its 4/21 Q1, separation on track for Q1-2027. Only in-window peer item: a Norges Bank disclosure of a new ~$293M GPC stake (6/3) — portfolio flow, not a fundamental signal. No peer issued negative guidance or a demand warning that would contaminate the AZO thesis.

**3. Fundamental developments.** **The PT-cut wave did NOT continue into the window — the critical finding.** Every post-print cut is dated 5/27–5/28 (pre-window, already priced at last review): Mizuho $3,600→$3,200 Neutral, Citi $4,300→$3,700 Buy, Morgan Stanley $4,020→$3,605 OW, JPMorgan $4,300→$3,850 OW, DA Davidson $4,300→$3,750 Buy, Roth $4,526→$4,023, Guggenheim $4,400→$4,000, BMO $4,300→$4,000, Baird $3,900→$3,600, Jefferies →$4,000 (Benzinga/MarketScreener/MarketBeat). The **only** in-window analyst action: **TD Cowen reiterated Buy, PT $3,700 (6/4)** — a constructive maintain ~+19% above spot. Supportive company news: **Vendor Summit 6/3** + announced **expansion of the mega-hub strategy (15 new locations)** reinforcing the DIFM/commercial supply-chain investment behind +10.4% domestic commercial growth (GlobeNewswire 6/3). Insider tone positive (director Brian Hannasch bought 165 sh 5/30; 3-mo skew to buys). No 8-K guidance revision in-window.

**4. Sector / macro context.** No demand-shock macro event in-window. Standing overhang is Mexico's Jan-2026 tariffs (on non-FTA auto parts) and US trade-policy/FX (peso) volatility — known at entry, reflected in the FX/margin caution already in PTs; nothing new crossed 6/1–6/5. Consumer-discretionary backdrop cautious-but-stable; the durable aftermarket bull point (aging US car parc, DIFM strength) is intact and directly reinforced by AZO's own mega-hub commercial push this week.

**5. Thesis-invalidation signals.**
- **(i) FY26 domestic SSS guide cut below 3% floor: NOT-TRIPPED.** No guidance update in-window; AZO gives no formal SSS guidance, and the last data point (fiscal Q3 5/26) was +4.1% cc / +5.5% reported domestic SSS — strongest in 3+ years.
- **(ii) Structural US auto-parts demand disruption (EV/ICE): NOT-TRIPPED.** No such program/event; aging-parc / DIFM thesis unchanged; mega-hub expansion is the opposite signal.
- **(iii) Sub-pattern-4 international-to-domestic contagion in guidance: NOT-TRIPPED.** No quarterly guidance event in-window and no analyst note this week framing domestic contagion.
- **Sub-pattern-4a PT-cut-wave watch — DE-ESCALATED.** The escalation trigger was "additional firms cut AND a PT taken to-or-below spot." In-window: **zero new cuts**; only TD Cowen's Buy/$3,700 maintain. No PT is at/below spot — the lowest target remains **Mizuho $3,200 (Neutral)**, still **above** the 6/5 spot ($3,116; ~+2.7%) and far above the ~$2,935 spot that prevailed at last review. PT cluster (~$3,200–$4,025, median ~$3,850–$4,000) sits ~+3% to ~+29% above spot — the signature of a sentiment overreaction reverting, NOT information-driven repricing. Watch flag **LOWERED** from heightened.

**6. Time to thesis resolution.** Materially improved. With the 6/5 spot of $3,116.43, the immutable target **$3,200 is only ~+2.7% above spot**, and ~47 days remain to the 7/24 stale-exit. AZO covered ~+6.2% in five sessions this week with no catalyst, so a further ~+2.7% to clear $3,200 within 47 days is now a high-probability outcome, with the PT median still ~+25%+ overhead providing pull. Main risk to resolution is mark volatility (broad-market or tariff/FX wobble) — which per B rules is not an exit trigger absent news.

**Recommendation: HOLD — APPROACHING TARGET.** No invalidation criterion tripped; the sub-pattern-4a PT-cut watch **de-escalated** (no new cuts, no PT at/below spot, lowest target Mizuho $3,200 still above spot); the only in-window analyst action was a TD Cowen Buy reiteration. Convergence target $3,200 is only ~+2.7% above spot with 47 days left — let the thesis run. **D1/D2 daily watch:** if AZO closes ≥ $3,200 on any session, stage the convergence SELL immediately per Strategy.md "Convergence target reached."

---

## Cross-Position & Macro Context (week ending Fri 2026-06-05)

- **Tape / macro:** The defining event was **Friday 6/5's hot May payrolls print (~172K, ~2× consensus; unemployment 4.3%)**, which spiked Treasury yields and drove a "good-news-is-bad-news" risk-off (Dow −695, S&P ~−2.6%, Nasdaq ~−4.2% — biggest daily drops since 2025; MarketWatch/CNBC/TheStreet 6/5). This reinforces the regime's reaccelerating-inflation + hawkish-policy axis (the FUNDAMENTAL_AXIS stagflation-tilt). High-beta/rate-sensitive names (ZBRA) bore the brunt; defensive/value names (TJX) showed relative strength. None of this flips a B criterion — the moves are macro marks, not position-specific news.
- **B router:** **ACTIVATE** confirmed (SPY Trend NEUTRAL ≠ DOWN; VIX ≠ HIGH; breadth HEALTHY). The single-day 6/5 risk-off does not flip the technical clauses; the monthly M1 owns formal re-derivation.
- **Portfolio correlation (KL #12):** four longs across four GICS sub-industries (Health Care Facilities; Communications Equipment/AIDC; Apparel Retail; Automotive Retail) — meaningfully more diversified than last cycle's six-name book; the prior TJX × BURL apparel-pair concentration is gone with BURL's exit. Per rev-35 this is monitoring, not a cap.
- **Scheduled catalysts inside open-position windows:**
  - **HCA:** no HCA-specific catalyst inside the ~20-day window (Q2 print 7/24 is after the 6/27 time-exit); Medicaid/SDP policy is already-priced slow-drip macro. → time-expiry path.
  - **ZBRA:** no in-window catalyst (Q2 print ~8/4 is after the 7/13 time-exit).
  - **TJX:** no in-window catalyst (Q2 FY27 print mid-to-late August, after the 7/24 time-exit); off-price-peer prints are sub-pattern monitoring inputs.
  - **AZO:** no in-window catalyst (Q4 FY26 print ~late September, after the 7/24 time-exit); FOMC 6/16–17 is a general consumer-discretionary read-through, not an AZO-specific criterion.
- **Convergence proximity ranking (D1/D2 watch priority):** AZO (+2.7% to $3,200) ≈ TJX (+2.4% to $164.50) are both within striking distance — first close ≥ target stages the convergence SELL. ZBRA (+13.7%) and HCA (+19.0%) are far from target; HCA's resolution is the 6/27 time-exit, ZBRA's the 7/13 time-exit absent a sharp rally.

---

## Summary Recommendation Table

| Position | Status | To convergence (6/5 close) | Recommendation | Cited criterion / key watch |
|----------|--------|-----------------------------|----------------|------------------------------|
| HCA  | OPEN | +19.0% (adverse, $372.13) | **HOLD — time-expiry watch ELEVATED** | Criteria (i)–(iv) NOT-TRIPPED; no B price-stop. ~20 days to 2026-06-27 time-exit; Bernstein PT $503→$413 (6/4) is adverse sentiment on already-priced Medicaid/SDP policy, not invalidation. Cited close rule at expiry: Strategy.md "Timeline expiry at 60 days." No W4 action — 6/27 time-exit handles staging. |
| ZBRA | OPEN | +13.7% ($264.00) | **HOLD** | Criteria (i)–(iv) NOT-TRIPPED; thesis intact (ZONE 2026 launches 6/2; William Blair reaffirmation 6/4). The −5.4% on 6/5 is macro-beta risk-off (adverse mark without news → not an exit trigger). 36 days to 7/13 time-exit; no in-window catalyst. |
| TJX  | OPEN | +2.4% ($164.50) | **HOLD — APPROACHING TARGET** | Criteria (i)–(iii) NOT-TRIPPED; relative strength on a −4% market day; ROST/BURL beats + LULU high-end miss corroborate trade-down. D1/D2: first close ≥ $164.50 → stage convergence SELL. |
| AZO  | OPEN | +2.7% ($3,200) | **HOLD — APPROACHING TARGET** | Criteria (i)–(iii) NOT-TRIPPED; sub-pattern-4a PT-cut watch **DE-ESCALATED** (zero new cuts in-window; lowest PT Mizuho $3,200 still above spot; TD Cowen Buy reiteration 6/4). D1/D2: first close ≥ $3,200 → stage convergence SELL. |

**IMMEDIATE-ACTION: NONE.** No tripped invalidation criterion. All four positions HOLD. AZO and TJX are within ~2.4–2.7% of convergence (D1/D2 first-close-above watch); HCA carries an elevated time-expiry watch (likely 6/27 60-day stale exit); ZBRA holds through a macro-driven adverse mark.
